an Endocrine Society Thematic Issue
Read our special collection of journal articles, published in 2020–2021, focused on lipids and adipocytes! Curation of the collection was guided by Altmetric Attention Scores and Featured Article designations.
In Endocrine Reviews, Marjot and colleagues discuss the contribution of changed lipid metabolism to fatty liver disease. Scheele and Wolfrum review the role of batokines, which are produced by brown adipocytes, in thermogenesis, and evaluate prospects for exploiting these molecules therapeutically. Pereira et al. describe the profound effects of leptin on lipid as well as glucose metabolism.
Schochat and colleagues describe in Endocrinology how they used a lipidomics approach in a zebrafish knockout to analyze the role of the key regulator of lipid homeostasis SREBF1. Wang et al. report the findings of a Mendelian randomization study that finds important effects of thyroid hormone levels on total cholesterol and low-density lipoprotein, but none in the reverse direction. Kothandapani and coauthors review the mechanisms behind the key role cholesterol plays in facilitating male sex differentiation.
In JCEM, Tofte et al. provide a meta-analysis on metabolomics investigations of factors associated with impaired renal function in patients with type 2 diabetes. They find multiple lipid species to be involved, with differential associations for different lipoprotein size classes. Sokooti and colleagues report on a study that parsed differential associations of high-density lipoproteins with the risk of developing type 2 diabetes. Dannecker and coauthors report finding an association between lower levels of low-density lipoprotein cholesterol and reduced insulin secretion, which could help explain the impaired glycemic control seen in patients prescribed cholesterol-lowering drugs.
Cook and colleagues, in Journal of the Endocrine Society, find benefits in clinical and quality-of-life measures from metreleptin, a recombinant modified leptin used to treat generalized and partial lipodystrophy. Lui and coauthors review various treatment options now available for familial hypercholesterolemia. And Iacobellis and Fricke find substantial and rapid reductions in epicardial fat thickness, a known cardiometabolic risk factor, when people with type 2 diabetes and obesity are treated with the GLP-1 receptor agonists dulaglutide or semaglutide, the latter recently approved by the US Food and Drug Administration for the treatment of obesity.
Published: June 2021
It can be difficult to keep up to date in the rapidly evolving and expanding world of endocrine science. We curate topical collections of research from across our journals, Endocrine Reviews, Endocrinology, Journal of the Endocrine Society, and The Journal of Clinical Endocrinology & Metabolism, so that you can easily find and read recent, influential articles on the topics that interest you.
Selection in each Thematic Issue is guided by online metrics, including Altmetric Attention Scores, Featured Article designations, and identification of leading authors and key topics. Each month, we publish a new Thematic Issue online and work to highlight and promote endocrine science in the press, through email, on social media and across other distribution channels.
Join our endocrine community and become a member! Only members receive access to a variety of member benefits that will enhance your career. If your membership has lapsed, rejoin today so that you can continue to receive your membership benefits.
We provide our journal authors with a variety of resources for increasing the discoverability and citation of their published work. Use these tools and tips to broaden the impact of your article.